Sponsor
Orpharma
20 PBAC submissions on file, active 2015–2024. 80% have been recommended.
Submissions
20
2015 → 2024
Win rate
80 %
16 recommended of 20 bucketable
Drugs
14 · 13 listed
unique molecules submitted
PBS spend captured
—
FY-latest govt benefit on owned drugs
Drug portfolio
Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.
Sodium phenylbutyrate
Metabolic · Recommended with restriction · 2019 — Amino acid formula with vitamins and minerals without phenylalanine
Metabolic · Recommended · 2024 other sponsor Amino acid formula without phenylalanine
Metabolic · Recommended · 2016 — Amino acid formula with carbohydrate without phenylalanine
Metabolic · Recommended · 2019 — Amino acid formula with carbohydrate, vitamins, minerals and trace elements without phenylalanine
Metabolic · Recommended · 2016 — Amino acid formula with fat, carbohydrate without methionine
Metabolic · Recommended with restriction · 2019 — Amino acid formula with fat, carbohydrate without phenylalanine and tyrosine
Metabolic · Recommended with restriction · 2019 — Amino acid formula with fat, carbohydrate, vitamins and minerals without phenylalanine
Metabolic · Recommended · 2024 — Amino acid formula with fat, carbohydrate, vitamins, minerals and long chain polyunsaturated fatty acids without phenylalanine and supplemented with docosahexaenoic acid
Metabolic · Recommended with restriction · 2016 — Amino acid formula with fat, carbohydrate, without valine, leucine and isoleucine
Metabolic · Recommended · 2019 — Amino acid formula with vitamins and minerals without phenylalanine and tyrosine
Metabolic · Recommended with restriction · 2020 other sponsor Amino acid formula with vitamins, minerals and long chain polyunsaturated fatty acids without phenylalanine
Metabolic · Recommended · 2024 other sponsor Arginine
Metabolic · Not recommended · 2017 — Citrulline
Metabolic · Recommended · 2015 — Therapy area mix
Activity by year 2015 (6) · 2016 (4) · 2017 (2) · 2018 (1) · 2019 (6) · 2024 (1)
Rejection patterns
Across 2 Not recommended decisions on file.
1× Clinically inappropriately high and undocumented protein content in the formulation1× lack of clinical need for an additional formulation of arginine on the PBS1× high protein levels (up to 20% of daily protein intake) could be detrimental to patients on highly restricted protein dietsOpen on full dashboard →
Part of script.report — an independent tracker of every PBAC Public Summary Document and the PBS expenditure that follows. Built from public data on pbs.gov.au . Not affiliated with the Australian Department of Health, PBAC, or any pharmaceutical company.
script.report extracts information discussed in PBAC Public Summary Documents (PSDs), not independently calculated values. Where figures such as ICERs are shown, they reflect what was discussed or referenced in committee documentation — not confirmed inputs. For authoritative cost-effectiveness data, refer to the original PSD.